Last reviewed · How we verify
liposomal amphotericin B + miltefosine
Liposomal amphotericin B targets fungal cell membranes, while miltefosine targets fungal cell membranes and inhibits sphingosine N-acyltransferase.
Liposomal amphotericin B targets fungal cell membranes, while miltefosine targets fungal cell membranes and inhibits sphingosine N-acyltransferase. Used for Visceral leishmaniasis.
At a glance
| Generic name | liposomal amphotericin B + miltefosine |
|---|---|
| Also known as | Impavido, AmBisome |
| Sponsor | Drugs for Neglected Diseases |
| Drug class | Antifungal |
| Target | Ergosterol, Sphingosine N-acyltransferase |
| Modality | Small molecule |
| Therapeutic area | Infectious Diseases |
| Phase | Phase 3 |
Mechanism of action
Liposomal amphotericin B works by binding to ergosterol in the fungal cell membrane, causing cell lysis and death. Miltefosine, on the other hand, inhibits the enzyme sphingosine N-acyltransferase, which is involved in the synthesis of sphingolipids, an essential component of fungal cell membranes. This dual mechanism of action makes liposomal amphotericin B + miltefosine a potent antifungal agent.
Approved indications
- Visceral leishmaniasis
Common side effects
- Nausea
- Vomiting
- Diarrhea
- Abdominal pain
- Fatigue
- Headache
- Rash
- Itching
- Dizziness
- Insomnia
Key clinical trials
- Study Comparing Several Drugs to Understand Which Work Against Cutaneous Leishmaniasis (CL) (PHASE3)
- Treatment of Mucosal Bolivian Leishmaniasis (PHASE3)
- Pilot Study: Oral Treatment of American Tegumentary Leishmaniasis (Cutaneous and Mucosal Forms) in the Elderly (PHASE2, PHASE3)
- Clinical Evaluation of a New Form of Cancer Therapy (Atavistic Chemotherapy) Based on the Principles of Atavistic Metamorphosis (2011) (PHASE2)
- Short Course Regimens for Treatment of PKDL (Sudan) (PHASE2)
- Efficacy Trial of Ambisome Given Alone and Ambisome Given in Combination With Miltefosine for the Treatment of VL HIV Positive Ethiopian Patients. (PHASE3)
- Clinical Trial to Assess the Safety and Efficacy of Sodium Stibogluconate (SSG) and AmBisome® Combination, Miltefosine and AmBisome® and Miltefosine Alone for the Treatment Visceral Leishmaniasis in Eastern Africa (PHASE2)
- Phase III, Study of Three Short Course Combo (Ambisome®, Miltefosine, Paromomycin) Compared With AmBisome for the Treatment of VL in Bangladesh (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: